Table 2.

Summary of hemoglobin outcome for the three dosing regimens stratified by IL28B and ITPA genetics (mean baseline hemoglobin is 14.9 g/dL)

	1,200/1,000	1,000/800	800/600
Steady‐state Hb, g/dL: median (5th–95th percentiles)
IL28B non‐CC, ITPA variant	11.5 (9.4, 13.9)	11.8 (9.6, 14.2)	12.1 (9.9, 14.2)
IL28B non‐CC, ITPA wild‐type	11.3 (8.8, 13.7)	11.7 (9.7, 13.8)	11.9 (9.8, 14.5)
IL28B CC, ITPA variant	10.5 (8.2, 12.7)	10.8 (8.5, 13.4)	11.3 (8.9, 13.8)
IL28B CC, ITPA wild‐type	10.2 (7.7, 13.3)	10.7 (8.2, 13.0)	11.1 (8.8, 13.4)
Steady‐state RBC lifespan, days: median (5th–95th percentiles)
IL28B non‐CC, ITPA variant	38.8 (17.1, 68.2)	43.9 (20.5, 72.7)	49.8 (25.2, 80.1)
IL28B non‐CC, ITPA wild‐type	33.7 (16.4, 61.8)	41.4 (20.3, 69.0)	45.6 (22.6, 77.0)
IL28B CC, ITPA variant	36.5 (19.3, 67.2)	42.9 (19.4, 70.3)	50.1 (26.1, 79.5)
IL28B CC, ITPA wild‐type	34.4 (15.4, 63.8)	40.9 (18.6, 68.7)	46.3 (23.0, 76.4)
W4 Hb decline, g/dL: median (5th–95th percentiles)
IL28B non‐CC, ITPA variant	−1.81 (−3.44, −0.17)	−1.66 (−3.39, −0.12)	−1.30 (−2.91, 0.06)
IL28B non‐CC, ITPA wild‐type	−2.43 (−4.33, −0.79)	−2.09 (−3.85, −0.42)	−1.79 (−3.32, −0.18)
IL28B CC, ITPA variant	−2.30 (−3.95, −0.44)	−1.99 (−4.08, −0.28)	−1.51 (−3.19, −0.05)
IL28B CC, ITPA wild‐type	−3.02 (−5.38, −1.06)	−2.55 (−4.63, −0.51)	−2.14 (−4.14, −0.49)
W12 Hb decline >3 g/dL (% subjects)
IL28B non‐CC, ITPA variant	39.2	31.2	21.6
IL28B non‐CC, ITPA wild‐type	52.8	37.6	28.8
IL28B CC, ITPA variant	75.8	63.6	45.2
IL28B CC, ITPA wild‐type	81.2	66.6	61.2
W12 Hb <10 g/dL (% subjects)
IL28B non‐CC, ITPA variant	13.4	9.8	6.4
IL28B non‐CC, ITPA wild‐type	17.6	9.0	7.2
IL28B CC, ITPA variant	38.6	29.0	18.0
IL28B CC, ITPA wild‐type	45.8	31.2	22.2

Hb, hemoglobin; IL, interleukin; ITPA, inosine triphosphatase; RBC, red blood cell.